Stockwinners Market Radar for October 07, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:45 EDT Costco CFO Galanti sells 2,000 common shares - In a regulatory filing, Costco executive VP and CFO Richard Galanti disclosed the sale of 2,000 common shares of the company on October 7 at a price of $471.1232 per share.

17:34 EDT Reunion Neuroscience general counsel Paula Amy Hewitt resigns - Reunion Neuroscience announced that Ronan Levy has resigned as director of the company and Paula Amy Hewitt has resigned as general counsel and corporate secretary, effective October 7. Additionally, the company has appointed Greg Mayes, president and CEO, Reunion, as director and Donna Wong, CFO, reunion, as corporate secretary, effective October 7.

17:03 EDT Singularity Future Technology receives noncompliance notice from Nasdaq - Singularity Future Technology announced that it received a notice from the Listing Qualifications Department of Nasdaq advising that the company's securities would be subject to delisting unless the company timely requests a hearing before a Nasdaq Hearings Panel. Accordingly, the company intends to timely request a hearing before the panel. The hearing request will stay any delisting or suspension action through October 25. Pursuant to the Nasdaq Listing Rules, in connection with the hearing request, the company will request that the automatic stay be extended through the conclusion of the hearings process and the expiration of any additional extension period granted by the panel following the hearing.

16:32 EDT Agile Therapeutics appoints Amy Welsh to chief commercial officer - Agile Therapeutics announced that it has reorganized and streamlined its executive leadership team to align with its business plan to promote Twirla transdermal system growth. As part of the changes, the company announced the appointment of Amy Welsh to chief commercial officer effective November 1. Additionally, James Tursi has informed the company that he will resign from the company's board of directors effective October 7. In addition to her current responsibilities leading the Twirla marketing team, Welsh, as chief commercial officer, will assume responsibility for all the company's commercial functions. Welsh joined the Company in May 2020 as VP, marketing. The company has also appointed Geoffrey Gilmore to the newly created role of chief administrative officer. In this role, Gilmore will be responsible for all the company's general and administrative functions, including corporate secretary, legal, human resources, finance, investor relations and quality assurance. The company's executive leadership team will also include Robert Conway, the company's chief corporate planning and supply chain officer, who will be responsible for the company's manufacturing and supply chain functions as well as corporate planning, and Paul Korner, the company's chief medical officer, who will be responsible for the Company's medical and research functions and will be part of the company's business development team.

16:19 EDT KalVista presents patient-centric data on use of PGI-C scale - KalVista Pharmaceuticals presented new data on patient-preferred on-demand treatment measures in hereditary angioedema, and on the effects that the disease has on quality of life for people living with HAE, at the 2022 HAEi Global Leadership Workshop in Frankfurt, Germany. KalVista presented supportive data for the use of the Patient Global Impression of Change scale as a clinical endpoint to assess the efficacy of on-demand treatments for HAE attacks. Qualitative interviews with people with HAE demonstrated clear preference for the PGI-C over other scales as a measurement tool for patient outcomes. These findings are consistent with post hoc analyses of the KalVista phase 2 clinical trial for sebetralstat, which found PGI-C to be a clinically meaningful measure of efficacy for on-demand treatment of HAE attacks. The combination of clinical meaningfulness and patient preference led KalVista to choose PGI-C as the primary outcome measure for the ongoing phase 3 KONFIDENT clinical trial. A second KalVista presentation highlighted the significant impact that HAE attacks have on the mental health, daily activities, and quality of life of people living with HAE. This research found that a majority of people with HAE missed out on important events in their lives due to anxiety associated with unpredictability of HAE attacks and that almost half the time, patients feel "less than their 100% self" because of HAE. "Despite many years of research in HAE, we are still gaining new insights on the impact of HAE attacks on the lives of people with the disease," said Andrew Crockett, Chief Executive Officer of KalVista. "The goal of this and other research we conduct is to better understand the consequences of HAE and to learn how improve the treatment experience for these patients with our pipeline of oral therapies."

16:05 EDT NovaBay receives NYSE American notice regarding share price - NovaBay Pharmaceuticals announced that on October 3, 2022 it received a notice from the NYSE American LLC that the company's common stock has been selling for a low price per share for a substantial period of time. As a result, pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the company must effect a reverse stock split of its common stock or otherwise demonstrate sustained price improvement within a reasonable period of time, which the NYSE American has determined to be no later than April 3, 2023, in order to continue its listing on the NYSE American. The company intends to take steps to improve its stock price, which include the filing of a definitive proxy statement with the Securities and Exchange Commission to hold a Special Meeting of Stockholders on November 10, 2022 seeking stockholder authorization of a reverse stock split at a ratio of between 1-for-10 and 1-for-35. The notice from the NYSE American has no immediate effect on the listing or trading of the company's common stock, and the common stock will continue to trade on the NYSE American.

14:39 EDT Meta identifies over 400 malicious Android, iOS apps aiming to steal login info - Meta (META) said it has identified more than 400 malicious Android and iOS apps this year that target people across the internet to steal their Facebook login information. These apps were listed on the Google Play Store and Apple's App Store and disguised as photo editors, games, VPN services, business apps and other utilities to trick people into downloading them. "We reported our findings to Apple (AAPL) and Google (GOOGL) and are helping potentially impacted people to learn more about how to stay safe and secure their accounts," Meta said. Reference Link

14:07 EDT AbbVie's Allergan to present eight scientific abstracts at ASDS meeting - Allergan Aesthetics, an AbbVie company, announced that eight scientific abstracts from its portfolio of aesthetic products and treatments will be presented at the American Society for Dermatologic Surgery, or ASDS, meeting taking place October 6-10. At the meeting, researchers will spotlight global post-marketing surveillance data on the reported rates of delayed-onset nodules presenting four or more weeks after injection of hyaluronic acid fillers based on the Vycross technology platform. The analyses of 15 years of data demonstrate the global reported rate of delayed-onset nodules associated with dermal fillers on the Vycross technology platform is low, the company said. Inflammatory nodules, which typically require intervention/treatment, were reported less frequently than non-inflammatory nodules. "Our scientific excellence continues to help drive advancements in aesthetic medicine, as well bring impactful treatments to our customers and patients globally. The data presented at ASDS reinforces our leadership in aesthetics and also the commitment of our research and development team to drive innovation for the industry and share learnings with the broader medical community" said Darin Messina, Senior Vice President, Allergan Aesthetics R&D.

13:01 EDT Baker Hughes reports U.S. rig count down 3 to 762 rigs

12:06 EDT Hallmark Financial to sell E&S lines operations to Core Specialty for $59.9M - Hallmark Financial Services announced the sale of its excess and surplus lines operations to Core Specialty Insurance Holdings for $40M cash consideration, plus an estimated $19.9M consideration for the acquisition costs associated with certain net unearned premium reserves. The transaction is comprised of nine business units within the Company's Specialty Commercial business segment, certain related assets and liabilities, and the immediate transition to Core Specialty of approximately 200 employees who produce and support these E&S lines businesses. Core Specialty's acquisition and assumption of the E&S businesses and the related assets and liabilities will be effective as of September 30, 2022. Certain key terms of the transaction include: Hallmark insurance subsidiaries will enter into a quota share reinsurance agreement with a Core Specialty insurance subsidiary to assume 100% of Hallmark's unearned premium reserves associated with the acquired E&S businesses, net of inuring third party reinsurance. The transaction includes the acquisition of Hallmark's agency subsidiary Heath XS, LLC, which does business as Hallmark E&S, and all data, agency relationships, intellectual property, lease arrangements and personnel related to the acquired E&S businesses. Core Specialty will not acquire any insurance company entities as part of the transaction, and the transaction excludes loss reserves associated with the acquired E&S businesses, which will be retained by Hallmark. The transaction does not include Hallmark's Standard Commercial business segment, Personal business segment, Aerospace & Programs business unit, the exited Binding Primary Auto business, or any business produced by third-party program managers, each of which will be retained by Hallmark. Hallmark expects the approximate $59.9M increase in statutory capital, gain on sale, and associated capital relief to strengthen its balance sheet and result in a more disciplined and streamlined company, better positioned to focus on the execution of its business strategies.

12:00 EDT Lithium Americas falls -10.7% - Lithium Americas is down -10.7%, or -$2.90 to $24.25.

12:00 EDT Direxion Daily Semiconductor Bull 3X Shares falls -16.3% - Direxion Daily Semiconductor Bull 3X Shares is down -16.3%, or -$1.82 to $9.37.

12:00 EDT Direxion Daily Semiconductor Bear 3X Shares rises 15.8% - Direxion Daily Semiconductor Bear 3X Shares is up 15.8%, or $8.51 to $62.23.

11:28 EDT SHF Holdings Inc trading resumes

11:23 EDT SHF Holdings Inc trading halted, volatility trading pause

11:14 EDT Pfizer-BioNTech omicron booster approved by Health Canada for ages 12 and up - Pfizer Canada (PFE) and BioNTech (BNTX) announced that Health Canada has authorized COMIRNATY Original & Omicron BA.4/BA.5 as a 30-undefined booster dose for individuals ages 12 years and older. An application for an Omicron BA.4/BA.5-adapted bivalent vaccine for children 5 through 11 years of age is also being planned for submission to Health Canada for review. The authorization of COMIRNATY Original & Omicron BA.4/BA.5 is based on clinical data from Pfizer and BioNTech's Monovalent, Omicron BA.1-adapted bivalent vaccine as well as pre-clinical and manufacturing data from their Omicron BA.4/BA.5-adapted bivalent vaccine. A clinical study investigating the safety, tolerability, and immunogenicity of the Omicron BA.4/BA.5-adapted bivalent vaccine in individuals 12 years of age and older is currently underway. This data will be provided to the authorities in the coming months. Pfizer and BioNTech's bivalent COVID-19 vaccine contains 15-undefined of mRNA encoding the spike protein of the wild-type of SARS-CoV-2, and 15-undefined of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariants. Because the Omicron BA.4 and BA.5 variants contain identical spike protein amino acid sequences, both can be targeted with a single mRNA strand. Apart from the addition of the mRNA sequence of the Omicron BA.4/BA.5 spike protein, all other components of the vaccine remain unchanged.

10:00 EDT Roblox falls -7.9% - Roblox is down -7.9%, or -$3.10 to $36.05.

10:00 EDT Direxion Daily Semiconductor Bull 3X Shares falls -10.6% - Direxion Daily Semiconductor Bull 3X Shares is down -10.6%, or -$1.19 to $10.00.

10:00 EDT Cano Health rises 10.0% - Cano Health is up 10.0%, or 88c to $9.72.

09:51 EDT Cano Health off highs, up 5% to $9.29 after trade resumption

09:47 EDT VeriSign Inc falls -6.7% - VeriSign Inc is down -6.7%, or -$1.12 to $15.44.

09:47 EDT Direxion Daily Semiconductor Bull 3X Shares falls -10.3% - Direxion Daily Semiconductor Bull 3X Shares is down -10.3%, or -$1.15 to $10.04.

09:47 EDT Direxion Daily Semiconductor Bear 3X Shares rises 10.1% - Direxion Daily Semiconductor Bear 3X Shares is up 10.1%, or $5.40 to $59.12.

09:43 EDT AMV Stock trading resumes

09:37 EDT BioSig Technologies executes purchase agreement with San Antonio Methodist - BioSig Technologies announced that San Antonio Methodist Hospital has acquired the PURE EP System.

09:33 EDT Desktop Health receives FDA clearance for SmileGuard resin - Desktop Health announced it has received U.S. Food and Drug Administration 510(k) clearance of SmileGuard resin, a breakthrough light-curable biocompatible material for the fabrication of strong and flexible bite splints and other orthodontic and dental appliances. SmileGuard resin, which is now available for ordering and shipping, solves a challenge among 3D printed bite sprint solutions in the marketplace today. Among the available options, the strongest materials are often uncomfortable to patients, while softer materials are often not as durable.

09:10 EDT PureTech sinks 18% after disclosing merger talks with Nektar - Shares of PureTech Health (PTRC) are moving lower after the company confirmed it is in takeover talks with Nektar Therapeutics (NKTR). PureTech confirmed that it has "exchanged indicative, non-binding proposals" with Nektar Therapeutics regarding a possible combination. PureTech and Nektar remain in discussions regarding the proposal, PureTech announced. Its stock in premarket trading is down 18% to $25.54 while Nektar is up 6c to $3.44.

09:09 EDT Oncorus announces publication on vRNA/LNP platform for cancer treatment - Oncorus announced the publication of preclinical data in Nature Communications highlighting the potential of its synthetic viral RNA/lipid nanoparticle platform as a novel approach to treating cancer by enabling repeat intravenous administration of viral immunotherapy. Data published today demonstrate vRNA/LNP delivery and selective replication, virus assembly, spread and lysis of tumor cells, leading to potent anti-tumor efficacy even in the presence of virus neutralizing antibodies in the bloodstream. The article describes the design and development of Oncorus' synthetic RNA viruses for the systemic treatment of cancer. The IV delivery of viral RNA genomes for two picornaviruses, Seneca Valley Virus and Coxsackievirus A21, was formulated in LNPs. By encapsulating vRNA in LNPs, Oncorus was able to recapitulate oncolytic viral therapy in various tumor cells and avoid neutralizing antibodies. The vRNA/LNP constructs were well tolerated and elicited tumor-specific in situ production of oncolytic virions, immune cell recruitment and tumor destruction. Efficacy was observed across multiple cancer models, including xenografts, PDX, GEMM and syngeneic models, with survival benefit observed in an orthotopic small cell lung cancer tumor model. Overall, synthetic RNA viruses were well tolerated after a single or multiple IV dose in mice and non-human primates. These results support the potential of this modality to expose all tumor lesions within a patient to a potently living drug that can both kill tumor cells and stimulate the immune system to fight cancer more effectively. Oncorus has built a pioneering platform addressing significant unmet needs in cancer immunotherapy treatment. This novel IV-administered approach involves encapsulating the RNA genomes of viruses known to kill cancer cells in an LNP, resulting in a vRNA/LNP immunotherapy. Oncorus' LNP delivery strategy is intended to be less immunogenic than a natural viral capsid and is designed to overcome the challenges caused by neutralizing antibodies. Using its platform, Oncorus has developed two vRNA/LNP immunotherapy programs, ONCR-021 and ONCR-788, which are based on CVA21 and SVV, respectively. The Company plans to submit an investigational new drug (application with the U.S Food and Drug Administration for ONCR-021 in mid-2023.

09:06 EDT PharmaCyte Biotech CEO Kenneth Waggoner steps down - PharmaCyte Biotech announces that its Board of Directors has empowered its Business Review Committee to evaluate opportunities to realize optimal shareholder value. In addition, CEO Kenneth Waggoner has stepped down from the position as CEO effective October 6, 2022. The Board has since appointed Joshua Silverman, a member of the Board, as interim CEO. Joshua Silverman is currently a director of PharmaCyte and the Co-Founder and Managing Member of Parkfield Funding LLC and is a former Principal and Managing Partner of Iroquois Capital Management.

09:01 EDT Infobird regains Nasdaq compliance - Infobird announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market on October 6, notifying the company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement and that the matter is now closed.

08:51 EDT Tanger Factory announces first Ulta Beauty store opening in Rehoboth Beach - Tanger Factory (SKT) announced the opening of Ulta Beauty (ULTA) at the Rehoboth Beach, Del. center. The 10,000-square-foot destination, which officially opened yesterday, is the first Ulta Beauty store within Tanger's portfolio, underscoring the company's ongoing strategy to expand its lineup of brands into new categories to meet consumers' unique needs.

08:38 EDT Microbot Medical acquires assets of Nitiloop, terms not disclosed - Microbot Medical acquired the assets of privately-held Nitiloop Ltd. The acquisition includes the NovaCross family of Microcatheters, a U.S. Food and Drug Administration cleared family of medical devices intended to facilitate the intraluminal placement of conventional and steerable guidewires beyond stenotic lesions, including chronic total occlusions, prior to PTCA or stent intervention. The NovaCross Microcatheter family, as a standalone device or when potentially integrated with the Company's One & Done technology, is expected to create a collection of procedure related kits that are customized for the LIBERTY Robotic System. The LIBERTY Robotic System is the first-ever disposable endovascular robotic system with remote operation capabilities and small footprint designed to reduce the requirement of capital investment and Cath Lab space. The Company expects this integration to help revolutionize and standardize the way endovascular procedures are conducted, while eliminating barriers to access and increasing the adoption rate of robotics in the endovascular space. The integration of technologies, such as the NovaCross Microcatheter family, fits well with the ecosystem strategy of the Company by allowing it to be competitive in the robotic as well as the instruments market for endovascular procedures, with the aim to integrate imaging and big data capabilities in the future. The Company believes the achievement of the LIBERTY Robotic System ecosystem will allow Microbot Medical to advance the adoption of robotics in the endovascular space, globally.

08:35 EDT Teva reaches agreement with Attorney General of Arkansas to settle opioid claims - Teva has reached an agreement with the Attorney General of Arkansas to settle the state's price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the state $931,000, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made. This is the fourth settlement of the price-fixing litigation that Teva has reached to date, having previously settled with Mississippi, Louisiana, and Georgia. The company said, :Teva is pleased to put these claims behind us, and we believe the modest settlement amount-in each of the four settlements to date-reflects our position on the allegations against us, which we continue to deny. We remain focused on delivering high-quality medicines to the patients around the world who need them, while also working cooperatively with state regulators to resolve legacy litigation matters in the United States, including these cases as well as the opioids cases. We are discussing settlements of the price-fixing litigation with additional states in an effort to continue replicating these results."

08:34 EDT NRSInsights says September same-store sales increased 9.5% - NRSInsights announced comparative same-store sales results for September 2022. The NRS retail network comprises over 20,000 terminals scanning purchases at independent retailers including bodegas, convenience stores, liquor stores, grocers, and tobacco and sundries sellers predominantly serving urban consumers. Retail Same-Store Sales Highlights for September 2022: Same-store sales increased 9.5% from a year earlier and decreased 1.2% compared to the preceding month; Same-store sales in the preceding month had increased 6.4% compared to the year-ago month and decreased 3.3% compared to the previous month; Year to date, same-store sales have increased 8.3% compared to the comparable period in 2021; For the three months ended September 30, 2022, same-store sales increased 9.1% compared to the three months a year ago; The number of items sold during September 2022 increased 8.1% compared to September 2021 and decreased 2.5% compared to August 2022; The average number of transactions per store in September 2022 increased 5.5% compared to September 2021 and decreased 2.4% compared to August 2022; A dollar-weighted average of prices for the top 500 items purchased in September 2022 increased 3.6% year over year, a rise compared to the 2.3% year-over-year increase in August 2022. Suzy Silliman, SVP, Data Strategy and Sales at NRS commented, "NRS same-store sales data for September shows continued sequential weakening of consumer demand although sales remain well above the year-ago levels because of exceptionally strong demand earlier in the year. Inflationary pressures intensified at our stores in September, but remain relatively modest compared to the headline inflation rates for the US economy."

08:31 EDT Pharvaris presents data on HAE drug development strategy - Pharvaris announced the presentation of preclinical and clinical data of PHA121, and its two formulations - softgel capsule PHVS416 and extended-release tablet PHVS719, for the treatment of HAE at the 2022 HAEi Global Leadership Workshop being held October 6-9, 2022, in Frankfurt, Germany. The poster, titled "Development of two novel oral formulations of a first-in-class bradykinin B2 receptor antagonist for on-demand and prophylactic treatment of hereditary angioedema," was presented by Marcus Maurer, M.D., Professor of Dermatology and Allergy, Executive Director of the Institute of Allergology at the Charite - Universitatsmedizin Berlin, and Co-Director of Allergology and Immunology at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP. The poster included preclinical and clinical data supporting Pharvaris' development strategy for two oral therapies, one for on-demand treatment and one for prophylactic treatment of HAE attacks. Preclinical in-vitro and ex-vivo studies demonstrate that PHA121, the active ingredient in PHVS416 and PHVS719, is 25-fold more potent than icatibant at inhibiting bradykinin activation of the endogenous human B2 receptor. Tailored formulations of PHA121 achieved exposure levels predicted from a human bradykinin challenge study to be effective in treating acute HAE attacks and reducing the likelihood of HAE attacks with a convenient single-dose oral administration. The poster included data supporting the suitability of the pharmacokinetics of PHVS416 for the on-demand treatment of HAE with therapeutic exposure above EC85 within 30 minutes and of PHVS719 daily for the prophylactic treatment of HAE with extended release and absorption from the GI tract providing the necessary therapeutic exposure for more than 24 hours.

08:12 EDT Greenlane appoints president Craig Snyder as CEO - Greenlane Holdings announced changes within the management team. Craig Snyder, Greenlane's current President, will take the helm as CEO effective January 1,2023. Nick Kovacevich, Greenlane's current CEO, will step into a Chief Corporate Development role and continue to support the company's key corporate development initiatives, including execution of the Company's previously disclosed liquidity plan, full time. Mr. Kovacevich will remain a member of Greenlane's board of directors after the transition to his new role. In addition to the planned change at CEO, the company also announced it is exploring making changes to the existing Board of Directors. The Nominating and Corporate Governance Committee of the Board is currently evaluating potential candidates with relevant skill sets in both CPG and technology to provide guidance and oversight as the company pursues this business transformation.

08:10 EDT Eskay Mining completes 29,500 m of diamond core drilling - Eskay Mining announced it has completed 29,500 m of diamond core drilling substantially fulfilling its planned meterage for the 2022 property wide exploration campaign. Over the past four months, drilling has been conducted at multiple volcanogenic massive sulfide targets including Jeff, Jeff North, Scarlet Ridge, Scarlet Valley, and Tarn Lake. Drilling has now been completed and the Company is currently demobilizing. "As the 2022 exploration season is drawing to a close, we have met all of our primary objectives," commented Dr. John DeDecker, Eskay Mining's VP of Exploration. "We have now drill tested the full extent of the TV-Jeff trend, conducted systematic mapping and extensive rock chip sampling of the Scarlet Ridge-Tarn Lake trend, and conducted exploratory drilling at three highly prospective and previously undrilled targets, Scarlet Ridge, Scarlet Valley and Tarn Lake. Our prospecting and mapping teams have also conducted reconnaissance level work at Spearhead, Vermillion, Tet, SIB-Lulu, Excelsior, and Harrymel Valley, laying the groundwork for an expansive push to drill test numerous additional targets in 2023. " Step-out drilling of the Upper Massive Sulfide Zone has confirmed that semi-massive and massive sulfide mineralization overlies the entire stockwork zone at TV thus significantly expanding the along-strike and down-dip extent of this important body of mineralization. Maiden drilling at Scarlet Valley and Tarn Lake yielded core displaying intense stockwork and replacement-style sulfide mineralization and hydrothermal alteration focused along east-west trending andesite dikes. Replacement-style mineralization and hydrothermal alteration of volcaniclastic debris flow breccia at Scarlet Valley provide an encouraging sign that the VMS feeder structures may have fed laterally extensive replacement-style mineralization along favorable stratigraphic horizons.

08:07 EDT Replimune Group secures $200M debt financing from Hercules Capital - Replimune Group (REPL) announced that it has obtained a $200M non-dilutive term loan facility from Hercules Capital (HTGC). This non-dilutive capital extends cash runway into 2025 ahead of key catalysts from the Company's registration-directed CERPASS and IGNYTE trials in cutaneous squamous cell carcinoma and anti-PD1 failed melanoma inclusive of the costs of funding commercial infrastructure and the running of a confirmatory study to support a potential BLA filing in anti-PD1 failed melanoma. The loan facility consists of up to six tranches, five of which can be drawn at Replimune's option and each maturing in October 2027. The loan facility provides for at least 48-months of interest-only at close, which interest-only period can be extended up to 60 months upon satisfaction of certain milestones. An initial $30M tranche was funded at closing with an additional $30M available to be drawn at Replimune's option prior to September 30, 2023. An additional $115M is available subject to the Company's achievement of specified performance milestones relating to clinical, regulatory, and commercial events. The final $25M tranche is available for draw, at Replimune's option and subject to Hercules consent during the interest-only period.

08:05 EDT Onfolio to acquire BWPS, SEOButler, terms not disclosed - Onfolio Holdings has entered into two separate definitive agreements to acquire all of the assets relating to file and password protection for the WordPress sites Prevent Direct Access and Password Protect WordPress and to acquire all of the outstanding shares of SEOButler. BWPS offers two main plugins that focus on file and password protection for WordPress sites, named Prevent Direct Access and Password Protect WordPress. They develop security plugins that allow bloggers, creators, agencies, and SMBs to protect their digital assets, products, and content. Offering a premium plugin in addition to the free products, users can access various free plugins, 20-30 distinct extensions, 2 other premium plugins, and more. BWPS reported approximately $379 thousand of adjusted EBITDA in 2021. SEOButler provides extensive products within the SEO niche including content, guest posting, social signals, and citations. SEOButler strives to be an innovator in the industry providing quality products and exceptional customer service at every part of the buying journey. In 2020, SEOButler built and deployed a custom-built Order Management System, designed to make the content creation process highly scalable while eliminating the bottlenecks that could otherwise impede the growth of a productized service business that relies primarily on human writers and editors. SEOButler reported $268 thousand of adjusted EBITDA in 2021.

08:03 EDT MICT, Inc. enters new merger agreement to acquire Tingo - MICT, Inc. (MICT) and Tingo announced the Company has signed a new merger agreement with Tingo, under new acquisition terms, whereby MICT is now acquiring 100% of the Operating Business and Assets of Tingo at the initial closing of the transaction, in return for the issuance by MICT of a combination of 19.9% of MICT's common stock and two series of convertible preference shares.The primary reasons for the new merger structure are to expedite the launch of Tingo's food-produce export business, as enabled through funding from MICT, benefiting from several high-margin and material export contracts that will allow the shift of a substantial part of Tingo's revenues directly into US dollars. The transaction also enables the acceleration of the development and launch of Tingo's commodity platform and commodity trading business. As previously reported in Tingo's Q2 2022 Form 10-Q, in the first half of 2022, Tingo's operating business reported revenue of $525.7 million, gross profit of $317.4 million, and net income before tax of $298.4 million, which equated to substantial growth as compared to the first half of 2021. In addition to its expected ongoing organic growth, the results of Tingo's operating business for the fourth quarter and second half of 2022 are expected to benefit significantly from several new business-streams, including the full launch of the Tingo Mobile super-app, the roll-out of the pan-African Visa partnership, and the launch of the food-produce export business. Upon initial closing, MICT welcomes two of the existing directors of Tingo onto its Board, namely John Brown and Kenneth Denos. The parties have entered into a new merger structure, which involves a three-step transaction, the first step of which is expected to close in November. As part of the new three step transaction structure, following receipt of the approval of Tingo's stockholders, MICT will acquire 100% of the operating business and assets of Tingo, and certain of Tingo's liabilities, in exchange for shares of MICT's common stock, representing 19.9% of its outstanding common stock; shares of a newly-formed Series A Convertible Preferred Stock, which will convert into an additional 20.1% of the issued and outstanding shares of MICT common stock, upon receipt of MICT stockholder approval; and shares of a newly-formed Series B Convertible Preferred Stock, which will convert into an additional 35% of the issued and outstanding shares of MICT common stock, upon receipt of MICT stockholder approval and Nasdaq change of control approval. In the event that all three steps are completed, Tingo would own 75% of MICT's common stock, based on the number of shares of common stock outstanding today. If MICT does not receive stockholder approval or Nasdaq does not approve the change of control, MICT will redeem the outstanding Series A Convertible Preferred and Series B Convertible Preferred, or potentially dilute its ownership in the acquired operating business and assets of Tingo. Additionally, in order to expedite the expansion of Tingo's operating business and its ability to enter into certain new contracts, MICT has approved a loan of $20 million to Tingo which it intends to fund within the upcoming days. Upon the closing of the transactions described above, the $20 million loan will be assumed by a wholly-owned subsidiary of MICT and remain outstanding as an intercompany loan.

07:44 EDT Open Lending announces Flynn to retire as CEO, Jezek to succeed - Open Lending announced last night that Keith Jezek has been appointed the company's new Chief Executive Officer and a member of its board of directors. After 21 years at Open Lending, co-founder John Flynn will retire as CEO and continue his role as Chairman of the Board, with Jezek assuming the responsibilities of CEO immediately. President and COO Ross Jessup, with whom Flynn founded the company in 2000, has also announced his retirement and transition to an advisory role, effective immediately. As part of this transition, Jessica Snyder, a current director who serves as Chair of the Audit Committee, has been appointed Vice Chair of the Board.

07:34 EDT Actelis releases ML600DM product line - Actelis Networks releases its new, powerful, ML600DM product line to customers. The ML600DM family of products consists of software managed, compact industrial switches offering rapid deployment of IoT networks, utilizing any existing infrastructure of fiber, copper or coax. Smart Cities, rail, highways, airports, utilities and military organizations can now digitize and modernize their installations with better, faster networking building blocks from Actelis, at a fraction of the time and cost, compared to all-new non-hybrid fiber networks.

07:31 EDT Sumo Logic, LambdaTest partner for test analytics - LambdaTest and Sumo Logic has announced a new joint partnership to help organizations leverage test analytics to scale their engineering efficiency. This partnership will enable customers to release faster with 360 degrees pipeline visibility and real-time insights of engineering practice within their development lifecycle. By analyzing security and operational issues with Sumo Logic, customers can make smarter decisions and free up resources for other critical functions.

07:21 EDT Iris Energy reports 325 bitcoin mined in September - Iris Energy published a monthly investor update for September 2022, containing its results from operations as well as construction and development updates. Key Highlights: Key metrics Sep-22; Average operating hashrate 2,729; Bitcoin mined 325; Mining revenue 6,224; Electricity costs 2,829; Revenue per Bitcoin 19,124; Electricity costs per Bitcoin 8,691; Corporate:Company's third operating site, Prince George, was energized on schedule, increasing total Company operating capacity by greater than60% to exceed 3.7 EH/s; Mackenzie expansion from 50MW to 80MW remains on track to be energized by end of Q4 2022, increasing expected near-term Company operating capacity to 4.7 EH/s; Initial 40MW planned at Childress to reach 6.0 EH/s; Reported record full year FY22 results. Operations:Average operating hashrate of 2,729 PH/s; Monthly operating revenue of US$6.2 million; 325 Bitcoin mined. Construction: Mackenzie: Expansion from 50MW to 80MW on track for energization by the end Q4 2022; Internal fit-out of the remaining 10MW of the third data center building progressing; Foundations complete and erection of structural steel has commenced for the fourth data center building. Childress: An initial 40MW development is planned at the 600MW site; Earthworks continued and foundation preparation commenced for the substation area and first data center building; Key civil, data center building and substation contractors mobilized on site.

07:14 EDT Arbe Robotics chosen by Veoneer for next generation radar - Arbe Robotics announced that Veoneer, an active safety tier-1, selected Arbe's chipset solution for its next generation radars, including a long-range, high resolution radar with 48x48 RF channels and a 360 degrees surround radar with 24x12 RF channels. Veoneer signed an agreement with Arbe confirming its plans to co-develop radars for automotive-grade safety and advanced driver assistance systems. The next generation radar is expected to be in pre-production by mid-2023.

07:11 EDT Red White & Bloom Brands continues 'aggressive' expansion plans - Red White & Bloom Brands announces that they are continuing their aggressive expansion plans, having recently announced the launch of Platinum Vape product extensions, the Company is focusing on expanded markets to serve. RWB previously announced that it entered into an exclusive license agreement that would see the full line of Platinum products be made available in Missouri and Massachusetts, with Platinum to be made available for sale in High Profile Cannabis shops and third-party retailers across both states. The Company reports that it has shipped the initial non-THC components to its partner as they gear up for manufacturing of finished goods for launch in both states. The initial offering will include the full collection of Platinum products in exciting new strains, flavors and formats. The Company is also pleased to report that RWB Florida has executed a lease for an additional medical dispensary location in Clearwater, FL. The new location design has been optimized for revenue per square foot and customer experience. All locations will carry the RWB full line of products and will help the Company expand more rapidly to serve a greater number of medical patients in the state. The Company expects the Clearwater location to be operating in Q4 of 2022. RWB is pleased to announce the appointment of Hans Sommer as General Manager of RWB Michigan. The Company further reports that it has issued 3,200,000 stock options to certain directors and an officer of the Company. The stock options are exercisable to acquire up to 3,200,000 common shares of the Company at an exercise price of $0.135. The stock options vest quarterly over a period of two years from grant.

07:07 EDT Tailwind Acquisition to transfer listing to NYSE American - Tailwind Acquisition announced that it will transfer its listing to the NYSE American, where it has been approved to list. In connection with the transfer, Tailwind will voluntarily delist from The New York Stock Exchange. TWND's decision to transfer to the NYSE American was motivated by several factors, including more favorable thresholds for continued listing on the NYSE American. Following the transfer, Tailwind intends to continue to file the same types of periodic reports and other information it currently files with the Securities and Exchange Commission. Tailwind anticipates the transfer to the NYSE American to occur on or about October 12.

07:06 EDT CytoSorbents CFO Kathleen Bloch to retire on March 31, 2023 - CytoSorbents announced that its CFO, Kathleen Bloch, MBA, CPA, plans to retire on March 31, 2023, following a distinguished decade-long career at the company. A search has been initiated for Bloch's replacement. Meanwhile, following her retirement next year, Bloch will continue as a consultant of the company to provide, among other services, continuity during the transition of her successor.

07:05 EDT Tilray reaffirms Adjusted EBITDA view $70M-$80M - Reaffirms guidance to be cash flow positive this year.

06:40 EDT AstraZeneca to present new data at ASCO GI and ASCO GU - AstraZeneca "will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionise cancer care at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, ASCO GI, and the 2022 ASCO Genitourinary Cancers Symposium, ASCO GU. A total of 35 abstracts from AstraZeneca will be featured across the two meetings. There will be two oral presentations at ASCO GI taking place 20 to 22 January, and an additional two oral presentations at ASCO GU taking place 17 to 19 February." Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca, said: "Our data will demonstrate the potential of our medicines to transform patient outcomes in liver, biliary tract and prostate cancers. Results from HIMALAYA and TOPAZ-1 will underscore our commitment to improving long-term survival for patients with liver and biliary tract cancers, and data from PROpel will raise the bar in treating 1st-line metastatic castration-resistant prostate cancer."Reference Link

06:01 EDT Credit Suisse announces plans to buy back $3B in debt - Credit Suisse Group announced offers by Credit Suisse International to repurchase certain OpCo senior debt securities for cash up to approximately CHF 3B. Credit Suisse announced that it is making a cash tender offer in relation to eight euro or pound sterling denominated senior debt securities for an aggregate consideration of up to EUR 1B. Concurrently, Credit Suisse is also announcing a separate cash tender offer in relation to twelve US dollar denominated senior debt securities for an aggregate consideration of up to $2B. Both offers are subject to various conditions as set out in the respective tender offer memoranda. The offers will expire on November 3, 2022 and November 10, 2022 respectively, subject to the terms and conditions set out in the offer documents. The company said: "The transactions are consistent with our proactive approach to managing our overall liability composition and optimizing interest expense and allow us to take advantage of market conditions to repurchase debt at attractive prices."

05:45 EDT Shopify settles textbook publishers' lawsuit over alleged piracy - Shopify has settled a lawsuit with five major education publishers that claimed the platform ignored notices of users selling pirated textbooks and other materials. The dispute with Macmillan Learning, Cengage Learning, Elsevier, McGraw Hill, and Pearson Education has been resolved and Shopify asked the court to dismiss the case with prejudice, according to the joint filing. Reference Link

05:10 EDT Waters announces EUR 6M investment to expand Wexford operations - Waters announced a combined investment of up to EUR 6M with support from IDA Ireland to expand its operations in Drinagh, Wexford to fund research and development, or R&D, of new clinical diagnostics products. The operational expansion at the Wexford facility will create new scientific jobs through 2024. Waters' Wexford facility is the company's primary site for manufacturing and delivery of its portfolio of in-vitro diagnostic, or IVD, systems, reagent kits, and software used by thousands of hospitals and laboratories worldwide for applications that include health screening for millions of newborn babies. Waters is formally making the announcement at its Wexford campus this afternoon with government and business leaders to mark 25 years of doing business in Ireland. The multi-year investment is part of Waters' strategic mission announced in 2021 to evaluate the potential of its mass spectrometry technologies for broader diagnostic solutions in areas of early disease detection such as cancer screening.